Interaction between the 5-HT system and the basal ganglia: Functional implication and therapeutic perspective in Parkinson's disease

Frontiers in Neural Circuits

Volumn 8, Issue MAR, 2014, Pages

  Miguelez, Cristina ^a   Morera Herreras, Teresa ^a   Torrecilla, Maria ^a   Ruiz Ortega, Jose A ^a   Ugedo, Luisa ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

5 HT; Basal ganglia; Electrophysiology; L DOPA induced dyskinesia; Parkinson's disease

Indexed keywords

LEVODOPA; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; ANTIPARKINSON AGENT;

BASAL GANGLION; BRAIN REGION; CAUDATE NUCLEUS; CELLULAR DISTRIBUTION; CHRONIC DRUG ADMINISTRATION; COGNITION; DORSAL RAPHE NUCLEUS; DRUG MECHANISM; DRUG SAFETY; DYSKINESIA; EMOTION; GLOBUS PALLIDUS; HUMAN; MEDIAN RAPHE NUCLEUS; MESENCEPHALON; MOTOR CONTROL; NERVE CELL NETWORK; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PUTAMEN; REVIEW; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; 5-HT; ELECTROPHYSIOLOGY; L-DOPA INDUCED DYSKINESIA; METABOLISM; NERVE CELL;

5-HT; BASAL GANGLIA; ELECTROPHYSIOLOGY; L-DOPA INDUCED DYSKINESIA; PARKINSON'S DISEASE;

ANTIPARKINSON AGENTS; BASAL GANGLIA; HUMANS; NEURONS; PARKINSON DISEASE; SEROTONIN;

EID: 84896957880     PISSN: 16625110     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncir.2014.00021     Document Type: Review

References (153)

1. Abramowski, D., Rigo, M., Duc, D., Hoyer, D., and Staufenbiel, M. (1995). Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 34, 1635-1645. doi: 10.1016/0028-3908(95)00138-7.
2. Aguiar, L. M., Macedo, D. S., Vasconcelos, S. M., Oliveira, A. A., De Sousa, F. C., and Viana, G. S. (2008). CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats. Brain Res. 1191, 192-199. doi: 10.1016/j.brainres.2007.11.051.
3. Aguiar, L. M., Nobre, H. V. Jr., Macedo, D. S., Oliveira, A. A., Freitas, R. M., Vasconcelos, S. M., et al. (2006). Neuroprotective effects ofcaffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol. Biochem. Behav. 84, 415-419. doi: 10.1016/j.pbb.2006.05.027.
4. Antonelli, T., Fuxe, K., Tomasini, M. C., Bartoszyk, G. D., Seyfried, C. A., Tanganelli, S., et al. (2005). Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58, 193-199. doi: 10.1002/syn.20195.
5. Arai, R., Karasawa, N., Geffard, M., and Nagatsu, I. (1995). L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett. 195, 195-198. doi: 10.1016/0304-3940(95)11817-G
6. Arborelius, L., Chergui, K., Murase, S., Nomikos, G. G., Hook, B. B., Chouvet, G., et al. (1993). The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn SchmiedebergsArch. Pharmacol. 347, 353-362. doi: 10.1007/BF00165384.
7. Aristieta, A., Morera-Herreras, T., Ruiz-Ortega, J. A., Miguelez, C., Vidaurrazaga, I., Arrue, A., et al. (2013). Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration. Psychopharmacology (Berl.). doi: 10.1007/s00213-013-3333-0. [Epub ahead ofprint].
8. Ba, M., Kong, M., Ma, G., Yang, H., Lu, G., Chen, S., et al. (2007). Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications. Brain Res. 1127, 177-184. doi: 10.1016/j.brainres.2006.10.020.
9. Balcioglu, A., Zhang, K., and Tarazi, F. I. (2003). Dopamine depletion abolishes apomorphine-and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Neuroscience 119, 1045-1053. doi: 10.1016/S0306-4522(03)00219-7.
10. Ballanger, B., Klinger, H., Eche, J., Lerond, J., Vallet, A. E., Le Bars, D., et al. (2012). Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov. Disord. 27, 84-89. doi: 10.1002/mds.23895.
11. Bartholini, G., Da Prada, M., and Pletscher, A. (1968). Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J. Pharm. Pharmacol. 20, 228-229. doi: 10.1111/j.2042-7158.1968.tb09726.x
12. Barwick, V. S., Jones, D. H., Richter, J. T., Hicks, P. B., and Young, K. A. (2000). Subthalamic nucleus microinjections of 5-HT2 receptor antagonists suppress stereotypyin rats. Neuroreport 11, 267-270. doi: 10.1097/00001756-20000207000009
13. Bengtson, C. P., Lee, D. J., and Osborne, P. B. (2004). Opposing electrophysiological actions of 5-HT on noncholinergic and cholinergic neurons in the rat ventral pallidum invitro. J. Neurophysiol. 92, 433-443. doi: 10.1152/jn.00543.2003.
14. Bibbiani, F., Oh, J. D., and Chase, T. N. (2001). Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57, 1829-1834. doi: 10.1212/WNL.57.10.1829.
15. Bishop, C., George, J. A., Buchta, W., Goldenberg, A. A., Mohamed, M., Dickinson, S. O., et al. (2012). Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur.J. Neurosci. 36,2839-2848. doi: 10.1111/j.1460-9568.2012.08202.x
16. Blomeley, C. P., and Bracci, E. (2009). Serotonin excites fast-spiking interneurons in the striatum. Eur. J. Neurosci. 29, 1604-1614. doi: 10.1111/j.1460-9568.2009.06725.x
17. Bonaventure, P., Hall, H., Gommeren, W., Cras, P., Langlois, X., Jurzak, M., et al. (2000). Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse 36, 35-46. doi: 10.1002/(SICI)1098-2396(200004)36:1<35::AID-SYN4>3.0.C0;2-Y
18. Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N., and Meco, G. (1994). Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 17, 73-82. doi: 10.1097/00002826-199402000-00008.
19. Bonsi, P., Cuomo, D., Ding, J., Sciamanna, G., Ulrich, S., Tscherter, A., et al. (2007). Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 32, 1840-1854. doi: 10.1038/sj.npp.1301294.
20. Borah, A., and Mohanakumar, K. P. (2007). Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell. Mol. Neurobiol. 27, 985-996. doi: 10.1007/s10571-007-9213-6.
21. Breese, G. R., Baumeister, A. A., McCown, T. J., Emerick, S. G., Frye, G. D., Crotty, K., et al. (1984). Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J. Pharmacol. Exp. Ther. 231, 343-354.
22. Bruinvels, A. T., Palacios, J. M., and Hoyer, D. (1993). Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 347, 569-582. doi: 10.1007/BF00166939.
23. Bufton, K. E., Steward, L. J., Barber, P. C., and Barnes, N. M. (1993). Distribution and characterization of the [3H]granisetron-labelled 5-HT3 receptor in the human forebrain. Neuropharmacology 32, 1325-1331. doi: 10.1016/0028-3908(93)90027-Z
24. Calon, F., Morissette, M., Rajput, A. H., Hornykiewicz, O., Bedard, P. J., and Di Paolo, T. (2003). Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord. 18, 241-253. doi: 10.1002/mds.10343.
25. Carta, M., Carlsson, T., Kirik, D., and Bjorklund, A. (2007). Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833. doi: 10.1093/brain/awm082.
26. Carta, M., Lindgren, H. S., Lundblad, M., Stancampiano, R., Fadda, F., and Cenci, M. A. (2006). Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 96, 1718-1727. doi: 10.1111/j.1471-4159.2006.03696.x
27. Castro, M. E., Pascual, J., Romon, T., Berciano, J., Figols, J., and Pazos, A. (1998). 5-HT1B receptor binding in degenerative movement disorders. Brain Res. 790, 323-328. doi: 10.1016/S0006-8993(97)01566-7.
28. Chen, L., Yung, K. K., Chan, Y. S., and Yung, W. H. (2008). 5-HT excites globus pallidus neurons by multiple receptor mechanisms. Neuroscience 151, 439-451. doi: 10.1016/j.neuroscience.2007.11.003.
29. Chinaglia, G., Landwehrmeyer, B., Probst, A., and Palacios, J. M. (1993). Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 54, 691-699. doi: 10.1016/0306-4522(93) 90240-G
30. Clemett, D. A., Punhani, T., Duxon, M. S., Blackburn, T. P., and Fone, K. C. (2000). Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39, 123-132. doi: 10.1016/S0028-3908(99)00 086-6
31. Collingridge, G. L., and Davies, J. (1981). The influence of striatal stimulation and putative neurotransmitters on identified neurones in the rat substantia nigra. BrainRes. 212, 345-359.doi: 10.1016/0006-8993(81)90467-4.
32. Commins, D. L., Shaughnessy, R. A., Axt, K. J., Vosmer, G., and Seiden, L. S. (1989). Variability among brain regions in the specificity of 6-hydroxydopamine (6-OHDA)-induced lesions. J. Neural Transm. 77, 197-210. doi: 10.1007/BF01248932.
33. Commissiong, J. W., and Sedgwick, E. M. (1979). Depletion of 5-HT by L-DOPA in spinal cord and brainstem of rat. Life Sci. 25, 83-86. doi: 10.1016/0024-3205(79)90493-4
34. Compan, V., Daszuta, A., Salin, P., Sebben, M., Bockaert, J., and Dumuis, A. (1996). Lesion study of the distribution of serotonin 5-HT4 receptors in rat basal ganglia and hippocampus. Eur. J. Neurosci. 8, 2591-2598. doi: 10.1111/j.1460-9568.1996.tb01553.x
35. Conti, M. M., Ostock, C. Y., Lindenbach, D., Goldenberg, A. A., Kampton, E., Dell'isola, R., et al. (2014). Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 77, 1-8. doi: 10.1016/j.neuropharm.2013.09.017.
36. D'Amato, R. J., Zweig, R. M., Whitehouse, P. J., Wenk, G. L., Singer, H. S., Mayeux, R., et al. (1987). Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann. Neurol. 22, 229-236. doi: 10.1002/ana.410220207.
37. Davies, J., and Tongroach, P. (1978). Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur. J. Pharmacol. 51, 91-100. doi: 10.1016/0014-2999(78)90333-3.
38. Delaville, C., Chetrit, J., Abdallah, K., Morin, S., Cardoit, L., De Deurwaerdere, P., et al. (2012a). Emerging dysfunctions consequent to combined monoamin-ergic depletions in Parkinsonism. Neurobiol. Dis. 45, 763-773. doi: 10.1016/j.nbd.2011.10.023.
39. Delaville, C., Navailles, S., and Benazzouz, A. (2012b). Effects ofnoradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism. Neuroscience 202, 424-433. doi: 10.1016/j.neuroscience.2011.11.024.
40. Di Matteo, V., Pierucci, M., Esposito, E., Crescimanno, G., Benigno, A., and Di Giovanni, G. (2008). Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog. Brain Res. 172, 423-463. doi: 10.1016/S0079-6123(08)00921-7.
41. Ding, S., Li, L., and Zhou, F. M. (2013). Presynaptic serotonergic gating of the subthalamonigral glutamatergic projection. J. Neurosci. 33, 4875-4885. doi: 10.1523/JNEUROSCI.4111-12.2013.
42. Dray,A., Gonye, T. J., and Oakley, N. R. (1976). Caudate stimulation andsubstantia nigra activity in the rat. J. Physiol. 259, 825-849.
43. Dupre, K. B., Eskow, K. L., Negron, G., and Bishop, C. (2007). The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinso-nian rat. Brain Res. 1158, 135-143. doi: 10.1016/j.brainres.2007.05.005.
44. Dupre, K. B., Ostock, C. Y., Eskow Jaunarajs, K. L., Button, T., Savage, L. M., et al. (2011). Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp. Neurol. 229, 288-299. doi: 10.1016/j.expneurol.2011.02.012.
45. Dupre, K. B., Ostock, C. Y., George, J. A., Eskow Jaunarajs, K. L., Hueston, C. M., and Bishop, C. (2013). Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats. ACS Chem. Neurosci. 4, 747-760. doi: 10.1021/cn300234z
46. el Mansari, M., and Blier, P. (1997). In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and orbitofrontal cortex. Neuropharmacology 36, 577-588. doi: 10.1016/S0028-3908(97)00035-X
47. el Mansari, M., Radja, F., Ferron, A., Reader, T. A., Molina-Holgado, E., and Descarries, L. (1994). Hypersensitivity to serotonin and its agonists in serotonin-hyperinnervated neostriatum after neonatal dopamine denervation. Eur. J. Pharmacol. 261, 171-178. doi: 10.1016/0014-2999(94)90316-6.
48. Eskow, K. L., Dupre, K. B., Barnum, C. J., Dickinson, S. O., Park, J. Y., and Bishop, C. (2009). The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63, 610-620. doi: 10.1002/syn.20630.
49. Everett, G. M., and Borcherding, J. W. (1970). L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science 168, 847-850. doi: 10.1126/science.168.3933.849.
50. Flores, G., Rosales, M. G., Hernandez, S., Sierra, A., and Aceves, J. (1995). 5-Hydroxytryptamine increases spontaneous activity of subthalamic neurons in the rat. Neurosci. Lett. 192, 17-20. doi: 10.1016/0304-3940(95) 11597-P
51. Fox, S. H., and Brotchie, J. M. (2000). 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord. 15, 1064-1069. doi: 10.1002/1531-8257(200011)15:6%3C1064::AID-MDS1002%3E3.0.CO
52. Frechilla, D., Cobreros, A., Saldise, L., Moratalla, R., Insausti, R., Luquin, M., et al. (2001). Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39, 288-296. doi: 10.1002/1098-2396(20010315)39:4<288::AID-SYN1011>3.0.CO;2-V
53. Gehlert, D. R., Schober, D. A., Gackenheimer, S. L., Mais, D. E., Ladouceur, G., and Robertson, D. W. (1993). Synthesis and evaluation of [125I]-(S)-iodozacopride, a high affinityradioligand for 5HT3 receptors. Neurochem. Int. 23, 373-383. doi: 10.1016/0197-0186(93)90081-F
54. Gerard, C., Martres, M. P., Lefevre, K., Miquel, M. C., Verge, D., Lanfumey, L., et al. (1997). Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res. 746, 207-219. doi: 10.1016/S0006-8993(96)01224-3
55. Gerber, R., Altar, C. A., and Liebman, J. M. (1988). Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl) 94, 178-182. doi: 10.1007/BF00176841.
56. Goetz, C. G., Damier, P., Hicking, C., Laska, E., Muller, T., Olanow, C. W., et al. (2007). Sarizotan as a treatment for dyskinesias in Parkinson's disease: double-blind placebo-controlled trial. Mov. Disord. 22, 179-186. doi: 10.1002/mds.21226
57. Goetz, C. G., Laska, E., Hicking, C., Damier, P., Muller, T., Nutt, J., et al. (2008). Placebo influences on dyskinesia in Parkinson's disease. Mov. Disord. 23, 700-707. doi: 10.1002/mds.21897.
58. Guiard, B. P., el Mansari, M., Merali, Z., and Blier, P. (2008). Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int. J. Neuropsychopharmacol. 11,625-639. doi: 10.1017/S1461145707008383.
59. Guttman, M., Boileau, I., Warsh, J., Saint-Cyr, J. A., Ginovart, N., Mccluskey, T., et al. (2007). Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 14, 523-528. doi: 10.1111/j.1468-1331.2007.01727.x
60. Haapaniemi, T. H., Ahonen, A., Torniainen, P., Sotaniemi, K. A., and Myllyla, V. V. (2001). [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov. Disord. 16, 124-130. doi: 10.1002/1531-8257(200101)16:1<124::AID-MDS1007>3.0. CO;2-R
61. Hall, H., Farde, L., Halldin, C., Lundkvist, C., and Sedvall, G. (2000). Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. Synapse 38,421-431. doi: 10.1002/1098-2396(20001215)38:4<421::AID-SYN7>3.0.CG;2-X
62. Halliday, G. M., Blumbergs, P. C., Cotton, R. G., Blessing, W. W., and Geffen, L. B. (1990). Loss of brainstem serotonin-and substance P-containing neurons in Parkinson's disease. Brain Res. 510, 104-107. doi: 10.1016/0006-8993(90) 90733-R
63. Hashimoto, K., and Kita, H. (2008). Serotonin activates presynaptic and postsy-naptic receptors in rat globus pallidus. J. Neurophysiol. 99, 1723-1732. doi: 10.1152/jn.01143.2007.
64. Horisawa, T., Ishiyama, T., Ono, M., Ishibashi, T., and Taiji, M. (2013). Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: analysis by [3H]SB-269970 autoradiography. Prog. Neuropsychopharmacol. Biol. Psychiatry 40, 132-137. doi: 10.1016/j.pnpbp.2012.08.005.
65. Hoyer, D., Pazos, A., Probst, A., and Palacios, J. M. (1986). Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res. 376, 97-107. doi: 10.1016/0006-8993(86)90903-0
66. Huot, P., Johnston, T. H., Koprich, J. B., Winkelmolen, L., Fox, S. H., and Brotchie, J. M. (2012a). Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiol. Aging 33, 207.e9-e19. doi: 10.1016/j.neurobiolaging.2010.09.011.
67. Huot, P., Johnston, T. H., Visanji, N. P., Darr, T., Pires, D., Hazrati, L. N., et al. (2012b). Increased levels of5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Mov. Disord. 27, 735-742. doi: 10.1002/mds.24964.
68. Huot, P., Johnston, T. H., Winkelmolen, L., Fox, S. H., and Brotchie, J. M. (2012c). 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiol. Aging 33, 194.e5-e15. doi: 10.1016/j.neurobiolaging.2010.04.035.
69. Iderberg, H., Francardo, V., and Pioli, E. Y. (2012). Animal models of L-DOPA-induced dyskinesia: an update on the current options. Neuroscience 211, 13-27. doi: 10.1016/j.neuroscience.2012.03.023.
70. Inden, M., Abe, M., Minamino, H., Takata, K., Yoshimoto, K., Tooyama, I., et al. (2012). Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model. J. Pharmacol. Sci. 119, 10-19. doi: 10.1254/jphs.12003FP
71. Jakeman, L. B., To, Z. P., Eglen, R. M., Wong, E. H., and Bonhaus, D. W. (1994). Quantitative autoradiography of 5-HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1. Neuropharmacology 33, 1027-1038. doi: 10.1016/0028-3908(94)90162-7.
72. Jellinger, K. (1990). New developments in the pathology ofParkinson's disease. Adv. Neurol. 53, 1-16.
73. Karstaedt, P. J., Kerasidis, H., Pincus, J. H., Meloni, R., Graham, J., and Gale, K. (1994). Unilateral destruction of dopamine pathways increases ipsi-lateral striatal serotonin turnover in rats. Exp. Neurol. 126, 25-30. doi: 10.1006/exnr.1994.1039.
74. Kaya, A. H., Vlamings, R., Tan, S., Lim, L. W., Magill, P. J., Steinbusch, H. W., et al. (2008). Increased electrical and metabolic activityin the dorsal raphe nucleus of Parkinsonian rats. Brain Res. 1221, 93-97. doi: 10.1016/j.brainres.2008.05.019.
75. Kelland, M. D., Freeman, A. S., and Chiodo, L. A. (1990). Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J. Pharmacol. Exp. Ther. 253, 803-811.
76. Kerenyi, L., Ricaurte, G. A., Schretlen, D. J., McCann, U., Varga, J., Mathews, W. B., et al. (2003). Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch. Neurol. 60, 1223-1229. doi: 10.1001/arch-neur.60.9.1223
77. Kilpatrick, G. J., Jones, B. J., andTyers, M. B. (1987). Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330, 746-748. doi: 10.1038/330746a0.
78. Kish, S. J., Tong, J., Hornykiewicz, O., Rajput, A., Chang, L. J., Guttman, M., et al. (2008). Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131, 120-131. doi: 10.1093/brain/awm239.
79. Kita, H., Chiken, S., Tachibana, Y., and Nambu, A. (2007). Serotonin modulates pallidal neuronal activity in the awake monkey. J. Neurosci. 27, 75-83. doi: 10.1523/JNEUROSCI.4058-06.2007.
80. Kleedorfer, B., Lees, A. J., and Stern, G. M. (1991). Buspirone in the treatment of levodopainduced dyskinesias. J. Neurol. Neurosurg. Psychiatry 54, 376-377. doi: 10.1136/jnnp.54.4.376-a
81. Knobelman, D. A., Kung, H. F., and Lucki, I. (2000). Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors. J. Pharmacol. Exp. Ther. 292, 1111-1117.
82. Kohen, R., Metcalf, M. A., Khan, N., Druck, T., Huebner, K., Lachowicz, J. E., et al. (1996). Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem. 66, 47-56. doi: 10.1046/j.1471-4159.1996.66010047.x
83. Lagiere, M., Navailles, S., Mignon, L., Roumegous, A., Chesselet, M. F., and Deurwaerdere, P. D. (2013). The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nuclues: electro-physiological correlates. Exp. BrainRes. 230,513-524. doi: 10.1007/s00221-013-3478-4
84. Lanfumey, L., and Hamon, M. (2000). Central 5-HT(1A) receptors: regional distribution and functional characteristics. Nucl. Med. Biol. 27, 429-435. doi: 10.1016/S0969-8051(00)00107-4.
85. Lavoie, B., and Parent, A. (1990). Immunohistochemical studyofthe serotoninergic innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol. 299, 1-16. doi: 10.1002/cne.902990102.
86. Liu, J., Chu, Y. X., Zhang, Q. J., Wang, S., Feng, J., and Li, Q. (2007). 5,7-dihydroxytryptamine lesion of the dorsal raphe nucleus alters neuronal activity of the subthalamic nucleus in normal and 6-hydroxydopamine-lesioned rats. BrainRes. 1149,216-222. doi: 10.1016/j.brainres.2007.02.052.
87. Lopez-Gimenez, J. F., Mengod, G., Palacios, J. M., and Vilaro, M. T. (2001). Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse 42, 12-26. doi: 10.1002/syn.1095.
88. Lucas, G., Di Matteo, V., De Deurwaerdere, P., Porras, G., Martin-Ruiz, R., Artigas, F., et al. (2001). Neurochemical and electrophysiological evidence that 5-HT4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic function. Eur. J. Neurosci. 13, 889-898. doi: 10.1046/j.0953-816x.2000.01453.x
89. Maeda, T., Kannari, K., Shen, H., Arai, A., Tomiyama, M., Matsunaga, M., et al. (2003). Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci. Lett. 343, 17-20. doi: 10.1016/S0304-3940(03)00295-7.
90. Martin-Cora, F. J., and Pazos, A. (2004). Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. Br. J. Pharmacol. 141, 92-104. doi: 10.1038/sj.bjp.07 05576
91. Mengod, G., Pompeiano, M., Martinez-Mir, M. I., and Palacios, J. M. (1990). Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res. 524, 139-143. doi: 10.1016/0006-8993(90)90502-3.
92. Mignon, L. J., and Wolf, W. A. (2005). 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 16, 699-703. doi: 10.1097/00001756-200505120-00009.
93. Miguelez, C., Berrocoso, E., Mico, J. A., and Ugedo, L. (2013). l-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats. Neuropharmacology 67, 349-358. doi: 10.1016/j.neuropharm.2012.11.016.
94. Miguelez, C., Grandoso, L., and Ugedo, L. (2011). Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease. Int. J. Neuropsychopharmacol. 14, 187-200. doi: 10.1017/S146114571000043X
95. Minabe, Y., Emori, K., and Ashby, C. R. Jr. (1996). The depletion of brain serotonin levels by para-chlorophenylalanine administration significantly alters the activity of midbrain dopamine cells in rats: an extracellular single cell recording study. Synapse 22, 46-53. doi: 10.1002/(SICI)1098-2396(199601)22:1%3C46::AID-SYN5%3E3.3.CO;2-I
96. Mo, J., Zhang, H., Yu, L. P., Sun, P. H., Jin, G. Z., and Zhen, X. (2010). L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neurobiol. Aging 31, 926-936. doi: 10.1016/j.neurobiolaging.2008.06.017.
97. Nahimi, A., Holtzermann, M., Landau, A. M., Simonsen, M., Jakobsen, S., Alstrup, A. K., et al. (2012). Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning. J. Neurochem. 120, 806-817. doi: 10.1111/j.1471-4159.2011.07598.x
98. Navailles, S., Benazzouz, A., Bioulac, B., Gross, C., and De Deurwaerdere, P. (2010a). High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J. Neurosci. 30, 2356-2364. doi: 10.1523/JNEUROSCI.5031-09.2010.
99. Navailles, S., Bioulac, B., Gross, C., and De Deurwaerdere, P. (2010b). Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol. Dis. 38, 136-143. doi: 10.1016/j.nbd.2010.01.012.
100. Navailles, S., Lagiere, M., Contini, A., and De Deurwaerdere, P. (2013). Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain. ACS Chem. Neurosci. 4, 680-692. doi: 10.1021/cn400046e
101. Nevalainen, N., Af Bjerken, S., Lundblad, M., Gerhardt, G. A., and Stromberg, I. (2011). Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia. J. Neurochem. 118, 12-23. doi: 10.1111/j.1471-4159.2011.07292.x
102. Nirogi, R., Kandikere, V., Bhyrapuneni, G., Saralaya, R., Ajjala, D. R., Aleti, R. R., et al. (2013). In-vivo rat striatal 5-HT4 receptor occupancy using non-radiolabelled SB207145. J. Pharm. Pharmacol. 65, 704-712. doi: 10.1111/jphp.12030
103. Oliver, K. R., Kinsey, A. M., Wainwright, A., and Sirinathsinghji, D. J. (2000). Localization of 5-ht(5A) receptor-like immunoreactivity in the rat brain. Brain Res. 867, 131-142. doi: 10.1016/S0006-8993(00)02273-3.
104. Olpe, H. R., and Koella, W. P. (1977). The response of striatal cells upon stimulation of the dorsal and median raphe nuclei. Brain Res. 122, 357-360. doi: 10.1016/0006-8993(77)90302-X
105. Palkovits, M., Brownstein, M., and Saavedra, J. M. (1974). Serotonin content of the brain stem nuclei in the rat. Brain Res. 80, 237-249. doi: 10.1016/0006-8993(74)90688-X
106. Park, M. R., Gonzales-Vegas, J. A., and Kitai, S. T. (1982). Serotonergic excitation from dorsal raphe stimulation recorded intracellularly from rat caudate-putamen. BrainRes. 243,49-58. doi: 10.1016/0006-8993(82)91119-2.
107. Pazos, A., Cortes, R., and Palacios, J. M. (1985). Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 346, 231-249. doi: 10.1016/0006-8993(85)90857-1.
108. Pazos, A., Probst, A., and Palacios, J. M. (1987). Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21, 123-139. doi: 10.1016/0306-4522(87)90327-7.
109. Politis, M., Wu, K., Loane, C., Kiferle, L., Molloy, S., Brooks, D. J., et al. (2010). Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 40, 216-221. doi: 10.1016/j.nbd.2010. 05.028
110. Pompeiano, M., Palacios, J. M., and Mengod, G. (1994). Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res. Mol. Brain Res. 23, 163-178. doi: 10.1016/0169-328X(94)90223-2
111. Prinz, A., Selesnew, L. M., Liss, B., Roeper, J., and Carlsson, T. (2013). Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease. Exp. Neurol. 248C, 236-245. doi: 10.1016/j.expneurol.2013.06.015.
112. Prisco, S., and Esposito, E. (1995). Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br. J. Pharmacol. 116, 1923-1931. doi: 10.1111/j.1476-5381.1995.tb16684.x
113. Querejeta, E., Oviedo-Chavez, A., Araujo-Alvarez, J. M., Quinones-Cardenas, A. R., and Delgado, A. (2005). In vivo effects oflocal activation and blockade of 5-HT1B receptors on globus pallidus neuronal spiking. Brain Res. 1043, 186-194. doi: 10.1016/j.brainres.2005.02.055.
114. Radja, F., Descarries, L., Dewar, K. M., and Reader, T. A. (1993). Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostri-atal dopamine neurons: a quantitative autoradiographic study. Brain Res. 606, 273-285. doi: 10.1016/0006-8993(93)90995-Y
115. Raisman, R., Cash, R., and Agid, Y. (1986). Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology 36, 556-560. doi: 10.1212/WNL.36.4.556.
116. Reijnders, J. S., Ehrt, U., Weber, W. E., Aarsland, D., and Leentjens, A. F. (2008). A systematic review of prevalence studies of depression in Parkinson's disease. Mov. Disord. 23, 183-189. doi: 10.1002/mds.21803.
117. Reynolds, G. P., Mason, S. L., Meldrum, A., De Keczer, S., Parnes, H., Eglen, R. M., et al. (1995). 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol. 114, 993-998. doi: 10.1111/j.1476-5381.1995.tb13303.x
118. Riahi, G., Morissette, M., Levesque, D., Rouillard, C., Samadi, P., Parent, M., et al. (2012). Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain. Neurochem. Int. 61, 1160-1171. doi: 10.1016/j.neuint.2012.08.009.
119. Riahi, G., Morissette, M., Parent, M., and Di Paolo, T. (2011). Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur. J. Neurosci. 33, 1823-1831. doi: 10.1111/j.1460-9568.2011.07675.x
120. Riahi, G., Morissette, M., Samadi, P., Parent, M., and Di Paolo, T. (2013). Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. Biochem. Pharmacol. 86, 970-978. doi: 10.1016/j.bcp.2013. 08.005
121. Rick, C. E., Stanford, I. M., and Lacey, M. G. (1995). Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2C receptors. Neuroscience 69, 903-913. doi: 10.1016/0306-4522(95)00283-O
122. Rozas, G., Liste, I., Guerra, M. J., and Labandeira-Garcia, J. L. (1998). Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci. Lett. 245, 151-154. doi: 10.1016/S0304-3940(98)00198-0.
123. Rueter, L. E., Tecott, L. H., and Blier, P. (2000). In vivo electrophysiolog-ical examination of 5-HT2 responses in 5-HT2C receptor mutant mice. Naunyn Schmiedebergs Arch. Pharmacol. 361, 484-491. doi: 10.1007/s0021099 00181
124. Rylander, D., Parent, M., O'Sullivan, S. S., Dovero, S., Lees, A. J., Bezard, E., et al. (2010). Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 68, 619-628. doi: 10.1002/ana.22097.
125. Saavedra, J. M. (1977). Distribution of serotonin and synthesizing enzymes in discrete areas of the brain. Fed. Proc. 36, 2134-2141.
126. Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., and Agid, Y. (1983). Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275, 321-328. doi: 10.1016/0006-8993(83)90 993-9
127. Hen, K. Z., and Johnson, S. W. (2008). 5-HT inhibits synaptic transmission in rat subthalamic nucleus neurons in vitro. Neuroscience 151, 1029-1033. doi: 10.1016/j.neuroscience.2007.12.001.
128. Shen, K. Z., Kozell, L. B., and Johnson, S. W. (2007). Multiple conductances are modulated by 5-HT receptor subtypes in rat subthalamic nucleus neurons. Neuroscience 148, 996-1003. doi: 10.1016/j.neuroscience.2007.07.012.
129. Sinton, C. M., and Fallon, S. L. (1988). Electrophysiological evidence for a functional differentiation between subtypes of the 5-HT1 receptor. Eur. J. Pharmacol. 157, 173-181. doi: 10.1016/0014-2999(88)90380-9.
130. Stanford, I. M., Kantaria, M. A., Chahal, H. S., Loucif, K. C., and Wilson, C.L. (2005). 5-Hydroxytryptamine induced excitation and inhibition in the subthalamic nucleus: action at 5-HT(2C), 5-HT(4) and 5-HT(1A) receptors. Neuropharmacology 49, 1228-1234. doi: 10.1016/j.neuropharm.2005.09.003.
131. Stanford, I. M., andLacey, M. G. (1996). Differential actions ofserotonin, mediated by 5-HT1B and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro. J. Neurosci. 16, 7566-7573.
132. Stefani, A., Surmeier, D. J., and Kitai, S. T. (1990). Serotonin enhances excitability in neostriatal neurons byreducing voltage-dependent potassium currents. Brain Res. 529, 354-357. doi: 10.1016/0006-8993(90)90851-2.
133. Steward, L. J., Bufton, K. E., Hopkins, P. C., Davies, W. E., and Barnes, N. M. (1993). Reduced levels of 5-HT3 receptor recognition sites in the putamen of patients with Huntington's disease. Eur. J. Pharmacol. 242, 137-143. doi: 10.1016/0014-2999(93)90073-Q
134. Takeuchi, Y., Sawada, T., Blunt, S., Jenner, P., and Marsden, C. D. (1991). Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats. Brain Res. 562, 301-305. doi: 10.1016/0006-8993(91)90635-9
135. Tronci, E., Lisci, C., Stancampiano, R., Fidalgo, C., Collu, M., Devoto, P., et al. (2013). 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model. Neurobiol. Dis. 60, 108-114. doi: 10.1016/j.nbd.2013.08.014.
136. Ugedo, L., Grenhoff, J., and Svensson, T. H. (1989). Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl) 98, 45-50. doi: 10.1007/BF00442004.
137. Vandermaelen, C. P., Bonduki, A. C., and Kitai, S. T. (1979). Excitation of caudate-putamen neurons following stimulation of the dorsal raphe nucleus in the rat. BrainRes. 175,356-361.doi: 10.1016/0006-8993(79)91016-3.
138. Vanover, K. E., Betz, A. J., Weber, S. M., Bibbiani, F., Kielaite, A., Weiner, D. M., et al. (2008). A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol. Biochem. Behav. 90, 540-544. doi: 10.1016/j.pbb.2008.04.010.
139. Varnas, K., Halldin, C., and Hall, H. (2004a). Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum. Brain Mapp. 22,246-260. doi: 10.1002/hbm.20035.
140. Varnas, K., Thomas, D. R., Tupala, E., Tiihonen, J., and Hall, H. (2004b). Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [3H]SB-269970. Neurosci. Lett. 367, 313-316. doi: 10.1016/j.neulet.2004.06.025.
141. Varnas, K., Halldin, C., Pike, V. W., and Hall, H. (2003). Distribution of 5-HT4 receptors in the postmortem human brain-an autoradiographic study using [125I]SB 207710. Eur. Neuropsychopharmacol. 13, 228-234. doi: 10.1016/S0924-977X(03)00009-9
142. Wang, H., Chen, X. Y., Chen, W. F., Xue, Y., Wei, L., and Chen, L. (2013). Anticataleptic effects of 5-HT1B receptors in the globus pallidus. Neurosci. Res. 77, 162-169. doi: 10.1016/j.neures.2013.09.002.
143. Wang, S., Zhang, Q. J., Liu, J., Wu, Z. H., Wang, T., Gui, Z. H., et al. (2009). Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT(1A) receptor stimulation in the rat. Neuroscience 159, 850-861. doi: 10.1016/j.neuroscience.2008.12.051.
144. Wilms, K., Vierig, G., and Davidowa, H. (2001). Interactive effects of cholecystokinin-8S and various serotonin receptor agonists on the firing activity of neostriatal neuronesin rats. Neuropeptides 35, 257-270. doi: 10.1054/npep.2001.0875.
145. Wong, E. H., Reynolds, G. P., Bonhaus, D. W., Hsu, S., and Eglen, R. M. (1996). Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders. Behav. Brain Res. 73, 249-252. doi: 10.1016/0166-4328(96)00106-4.
146. Xiang, Z., Wang, L., and Kitai, S. T. (2005). Modulation of spontaneous firing in rat subthalamic neurons by 5-HT receptor subtypes. J. Neurophysiol. 93, 1145-1157. doi: 10.1152/jn.00561.2004.
147. Yakel, J. L., Trussell, L. O., and Jackson, M. B. (1988). Three serotonin responses in cultured mouse hippocampal and striatal neurons. J. Neurosci. 8, 1273-1285.
148. Yamada, H., Aimi, Y., Nagatsu, I., Taki, K., Kudo, M., and Arai, R. (2007). Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci. Res. 59, 1-7. doi: 10.1016/j.neures.2007. 05.002
149. Zhang, Q. J., Gao, R., Liu, Y. P., andWang, S. (2007a). Changes in the firing activity of serotonergic neurons in the dorsal raphe nucleus in a rat model ofParkinson's disease. ShengLi Xue Bao 59, 183-189.
150. Zhang,X., Andren, P. E., andSvenningsson, P. (2007b). Changes on 5-HT(2) receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiol. Behav. 92, 29-33. doi: 10.1016/j.physbeh.2007.05.033.
151. Zhang, S. J., Wang, H., Xue, Y., Yung, W. H., and Chen, L. (2010). Behavioral and electrophysiological effects of 5-HT in globus pallidus of 6-hydroxydopamine lesioned rats. J. Neurosci. Res. 88, 1549-1556. doi: 10.1002/jnr. 22325
152. Zhang, X., Andren, P. E., Greengard, P., and Svenningsson, P. (2008). Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 105, 2163-2168. doi: 10.1073/pnas.0711839105.
153. Zhou, F. C., Bledsoe, S., and Murphy, J. (1991). Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 556, 108-116. doi: 10.1016/0006-8993(91)90553-8